**Core Concept**
Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia due to insulin deficiency or resistance. Macrovascular effects of DM include atherosclerosis and increased risk of cardiovascular disease, while microvascular effects include nephropathy, retinopathy, and neuropathy. Effective management of DM requires drugs that not only control blood glucose levels but also halt or prevent these secondary complications.

**Why the Correct Answer is Right**
Pioglitazone is a thiazolidinedione (TZD) that activates peroxisome proliferator-activated receptor-gamma (PPAR-γ). Activation of PPAR-γ enhances insulin sensitivity, improves glycemic control, and has anti-inflammatory effects. Pioglitazone specifically halts macrovascular effects of DM by reducing the risk of myocardial infarction and stroke. Additionally, it prevents microvascular complications by reducing albuminuria and slowing the progression of diabetic nephropathy.

**Why Each Wrong Option is Incorrect**
**Option A:** Metformin is a biguanide that primarily reduces hepatic glucose production and increases insulin sensitivity. While it is effective in managing type 2 DM, it does not specifically halt macrovascular as well as microvascular effects of DM.
**Option B:** Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances glucose-dependent insulin secretion. It is effective in managing type 2 DM but does not prevent macrovascular complications.
**Option C:** Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells. While it is effective in managing type 2 DM, it does not prevent microvascular complications.

**Clinical Pearl / High-Yield Fact**
TZDs like pioglitazone are particularly effective in preventing microvascular complications of DM, such as diabetic nephropathy. However, their use is limited by the risk of fluid retention and heart failure.

**Correct Answer:** C. Pioglitazone